BACKGROUND: Impairment of olfactory function is a well recognized nonmotor manifestation of Parkinson’s disease(PD). The aim of this investigation was to determine if the MAO-B inhibitor rasagiline can improve olfaction in PD patients. METHODS:Thirty-four PD patients participated in this single-center, prospective, randomized, controlled,double-blind study. Seventeen patients were randomly assigned to rasagiline and 17 patients to placebo. Orthoand retronasal olfactory testing and recording of event related potentials were performed before and after 120 days of rasagiline versus placebo intake. RESULTS: When comparing olfactory score differences between baseline and after 120 days between the 2 groups, the level of significance was not reached. CONCLUSIONS: The primary end point of the study was not reached, and therefore, a specific effect of rasagiline on olfactory function in PD could not be demonstrated.
RCT Entities:
BACKGROUND: Impairment of olfactory function is a well recognized nonmotor manifestation of Parkinson’s disease(PD). The aim of this investigation was to determine if the MAO-B inhibitor rasagiline can improve olfaction in PDpatients. METHODS: Thirty-four PDpatients participated in this single-center, prospective, randomized, controlled,double-blind study. Seventeen patients were randomly assigned to rasagiline and 17 patients to placebo. Orthoand retronasal olfactory testing and recording of event related potentials were performed before and after 120 days of rasagiline versus placebo intake. RESULTS: When comparing olfactory score differences between baseline and after 120 days between the 2 groups, the level of significance was not reached. CONCLUSIONS: The primary end point of the study was not reached, and therefore, a specific effect of rasagiline on olfactory function in PD could not be demonstrated.
Authors: Elisabeth B Lucassen; Nicholas W Sterling; Eun-Young Lee; Honglei Chen; Mechelle M Lewis; Lan Kong; Xuemei Huang Journal: Mov Disord Date: 2014-05-16 Impact factor: 10.338